Sensorium Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 26

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $30M

  • Investors
  • 16

Sensorium Therapeutics General Information

Description

Developer of a therapeutic discovery platform designed for the identification of compounds to treat brain and mental health conditions. The company's platform integrates artificial intelligence, chemistry, and neuroscience to mine biological relationships, enabling researchers to develop nature-derived psychoactive medicines for social anxiety, drug-resistant epilepsy, and cognitive impairment.

Contact Information

Website
www.sensorium.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 40 Guest Street
  • Boston, MA 02135
  • United States
+1 (562)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Drug Delivery
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
Corporate Office
  • 40 Guest Street
  • Boston, MA 02135
  • United States
+1 (562)

Sensorium Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sensorium Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A1) 15-Jul-2025 $30M Completed Clinical Trials - Phase 1
3. Debt - General 01-Feb-2024 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 23-Sep-2022 $24.7M $33.7M Completed Startup
1. Seed Round 23-Jul-2021 $9M $9M Completed Startup
To view Sensorium Therapeutics’s complete valuation and funding history, request access »

Sensorium Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-3
Series A-2
Series A-1 18,065,856 $0.000100 6% $0.5 $0.5 1x $0.5 24.98%
To view Sensorium Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Sensorium Therapeutics Patents

  • 62

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 27

    Pending

  • Expiring in next 12 mo

Sensorium Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025122822-A1 Therapeutic alkaloid compounds Inactive 06-Dec-2023
WO-2025111234-A1 Therapeutic alkaloid compounds Inactive 20-Nov-2023
AU-2024376801-A1 Therapeutic alkaloid compounds Active 10-Nov-2023
AU-2024376801-B2 Therapeutic alkaloid compounds Active 10-Nov-2023
AU-2024376801-C1 Therapeutic alkaloid compounds Active 10-Nov-2023 A61K31/404
To view Sensorium Therapeutics’s complete patent history, request access »

Sensorium Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sensorium Therapeutics Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Dolby Family Ventures Venture Capital Minority
Hatteras Venture Partners Venture Capital Minority
Mission BioCapital Venture Capital Minority
Mockingbird Capital Partners Venture Capital Minority
Bonaventure Equity Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial

Sensorium Therapeutics FAQs

  • When was Sensorium Therapeutics founded?

    Sensorium Therapeutics was founded in 2021.

  • Where is Sensorium Therapeutics headquartered?

    Sensorium Therapeutics is headquartered in Boston, MA.

  • What is the size of Sensorium Therapeutics?

    Sensorium Therapeutics has 26 total employees.

  • What industry is Sensorium Therapeutics in?

    Sensorium Therapeutics’s primary industry is Drug Discovery.

  • Is Sensorium Therapeutics a private or public company?

    Sensorium Therapeutics is a Private company.

  • What is Sensorium Therapeutics’s current revenue?

    The current revenue for Sensorium Therapeutics is .

  • How much funding has Sensorium Therapeutics raised over time?

    Sensorium Therapeutics has raised $69.7M.

  • Who are Sensorium Therapeutics’s investors?

    Dolby Family Ventures, Hatteras Venture Partners, Mission BioCapital, Mockingbird Capital Partners, and Bonaventure Equity are 5 of 16 investors who have invested in Sensorium Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process